Log in

NASDAQ:ODTOdonate Therapeutics Stock Price, Forecast & News

$40.12
-2.39 (-5.62 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$40.00
Now: $40.12
$43.50
50-Day Range
$27.78
MA: $36.08
$45.63
52-Week Range
$18.07
Now: $40.12
$46.50
Volume52,800 shs
Average Volume114,465 shs
Market Capitalization$1.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.15
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Read More
Odonate Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.05 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ODT
CUSIPN/A
Phone858-731-8180

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.06 per share

Profitability

Net Income$-111,820,000.00

Miscellaneous

Employees117
Market Cap$1.29 billion
Next Earnings Date7/22/2020 (Estimated)
OptionableNot Optionable

Receive ODT News and Ratings via Email

Sign-up to receive the latest news and ratings for ODT and its competitors with MarketBeat's FREE daily newsletter.

Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions

How has Odonate Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ODT stock has increased by 54.7% and is now trading at $40.12. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Odonate Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View analyst ratings for Odonate Therapeutics.

When is Odonate Therapeutics' next earnings date?

Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Odonate Therapeutics.

How were Odonate Therapeutics' earnings last quarter?

Odonate Therapeutics Inc (NASDAQ:ODT) posted its earnings results on Tuesday, April, 28th. The company reported ($0.99) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.03) by $0.04. View Odonate Therapeutics' earnings history.

What price target have analysts set for ODT?

1 equities research analysts have issued 1 year target prices for Odonate Therapeutics' shares. Their forecasts range from $26.00 to $26.00. On average, they expect Odonate Therapeutics' stock price to reach $26.00 in the next year. This suggests that the stock has a possible downside of 35.2%. View analysts' price targets for Odonate Therapeutics.

Has Odonate Therapeutics been receiving favorable news coverage?

News headlines about ODT stock have been trending negative this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Odonate Therapeutics earned a news sentiment score of -2.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the company's share price in the immediate future. View the latest news about Odonate Therapeutics.

Who are some of Odonate Therapeutics' key competitors?

What other stocks do shareholders of Odonate Therapeutics own?

Who are Odonate Therapeutics' key executives?

Odonate Therapeutics' management team includes the following people:
  • Mr. Kevin C. Tang, Chairman & CEO (Age 52)
  • Mr. John G. Lemkey, Chief Operating Officer (Age 38)
  • Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 65)
  • Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)
  • Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 43)

When did Odonate Therapeutics IPO?

(ODT) raised $150 million in an IPO on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Cowen was co-manager.

What is Odonate Therapeutics' stock symbol?

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

How do I buy shares of Odonate Therapeutics?

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Odonate Therapeutics' stock price today?

One share of ODT stock can currently be purchased for approximately $40.12.

How big of a company is Odonate Therapeutics?

Odonate Therapeutics has a market capitalization of $1.29 billion. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe.

What is Odonate Therapeutics' official website?

The official website for Odonate Therapeutics is www.odonate.com.

How can I contact Odonate Therapeutics?

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.